



NECTAR LIFESCIENCES LIMITED

Corporate Identity Number (CIN): L24232PB1995PLC016664

Registered Office: Shop No. 5, SL Enclave, Behind Sohi HP Gas Agency,
Barwala Road, Dera Bassi, Distt. S.A.S Nagar, Punjab 140507, India

Tel. No.: +91-172- 5078200, 5001687; Email: cs@neclife.com; Website: www.neclife.com

Contact Person: Mr. Sanjaymohan Singh Rawat, Company Secretary and Compliance Officer

CORRIGENDUM FOR PUBLIC ANNOUNCEMENT FOR THE ATTENTION OF EQUITY SHAREHOLDERS/BENEFICIAL OWNERS OF EQUITY SHARES OF NECTAR LIFESCIENCES LIMITED FOR THE BUYBACK OF EQUITY SHARES THROUGH TENDER OFFER UNDER SECURITIES AND EXCHANGE BOARD OF INDIA (BUY-BACK OF SECURITIES) REGULATIONS, 2018, AS AMENDED.

This corrigendum to Public Announcement (“**Corrigendum**”) should be read in continuation of and in conjunction with the public announcement dated Dec 04, 2025 (“**PA**”), which was published in this newspaper on December 05, 2025. Capitalised terms used but not defined in this Corrigendum shall have the same meanings as ascribed in the PA unless otherwise defined.

Equity Shareholders are requested to note the modification/changes made in some figures necessitated to be made in the Public Announcement, due to some inadvertent typographical errors.

1. The paragraph 7.2(a). of the Public Announcement is modified as under:

Aggregate of Equity Shares purchased or sold by the Promoters and Promoter Group of the Company:

Name of Shareholder	Aggregate No. of Equity Shares purchased or sold	Nature of Transaction	Maximum Price (₹)	Date of Maximum Price	Minimum Price (₹)	Date of Minimum Price
Raman Goyal	838448	Purchase (Market)	15.60	August 22, 2025	14.24	August 18, 2025
Sanjiv Goyal	55845600	Revocation of Pledge	NA	-	NA	-
Sanjiv (HUF)	43622400	Revocation of Pledge	NA	-	NA	-
Sanjiv Goyal	8000000	Gift Given (Off market)	NA	-	NA	-
Raman Goyal	8000000	Gift Received (Off market)	NA	-	NA	-

2. The paragraph 7.2(c). of the Public Announcement is modified as under:

Aggregate shares purchased or sold by the Directors and Key Managerial Personnel of the Company: Except as disclosed below, none of our directors and key managerial personnel have purchased or sold any Equity Shares in the last six months preceding the date of the Board Meeting at which the Buyback was approved, i.e., Dec.03, 2025,

Sr. No	Name of Shareholder	No. of Equity Shares	Nature of Transaction	Date of Transaction	Price Per Equity Share
1	Sanjiv Goyal	55845600	Revocation of Pledge	October 29, 2025	0.00/-
2	Sanjiv Goyal	8000000	Gift Given (Off market)	November 27, 2025	0.00/-

3. The paragraph 12 -Annexure A. of the Public Announcement is modified as under:

Annexure A

STATEMENT OF PERMISSIBLE CAPITAL PAYMENT

Computation of amount of permissible capital payment towards buyback of equity shares of Nectar Lifesciences Limited in accordance with Regulation 4(i) read with proviso of Regulation 5(i)(b) of the Securities and Exchange Board of India (Buy-Back of Securities) Regulations, 2018 and Section 68(2)(b)(i) of the Companies Act, 2013, as amended based on both the audited standalone financial statements and the audited consolidated financial statements as at March 31, 2025:

Amount (Rs. in Lakhs)

Particulars	Standalone	Consolidated
A. Paid-up Equity Share Capital (22,42,60,970 equity shares of ₹ 1/- each fully paid up)	2242.61	2242.61
B. Free Reserves*		
Securities premium account	32879.85	32879.85
Surplus in statements of profit and loss	59078.68	59078.02
General Reserves	1410.20	1410.20
Less Intangible Assets	(5650.43)	(5650.43)
Total Free Reserves	87718.30	87717.64
Total of Paid-up Equity Share Capital and Free Reserves (A+B)	89960.91	89960.25
Maximum amount permissible for buyback under Section 68 of the Companies Act, as amended read with Regulation 4(i) of the SEBI Buyback Regulations (25% of the total paid-up equity capital and free reserves)	22490.23	22490.06
Proposed capital payment restricted to 10% of the total paid-up equity capital and free reserves under proviso to Section 68(2)(b)(i) of the Act and the proviso to Regulation 5(i)(b) of the SEBI Buyback Regulation within the powers of the Board of Directors	8996.09	8996.03

*Free reserves as defined in Section 2(43) of the Companies Act, 2013 read along with Explanation II provided in Section 68 of the Companies Act, 2013, as amended.

Note: The amounts have been extracted from the audited standalone and consolidated financial statements of the Company as at and for the year ended March 31, 2025.

Note: The impact of taxes on Buy-back and transaction costs related of Buy-back is not considered.

Except as detailed in this Corrigendum, the other contents and terms in the PA remain unchanged. A copy of this Corrigendum is expected to be available on the websites of SEBI (www.sebi.gov.in), Stock Exchanges (www.bseindia.com and www.nseindia.com), the Company (www.neclife.com) and the Manager to the Buyback (www.mastertust.co.in).

In terms of Regulation 24(i)(a) of the Buyback Regulations, the Board of Directors accepts responsibility for all the information contained in this Corrigendum and confirms that such document contains true, factual and material information and does not contain any misleading information.

For and on behalf of the Board of Directors of Nectar Lifesciences Limited

Sd/-	Sd/-	Sd/-
Sanjiv Goyal Chairperson and Managing Director DIN: 00002841 Place : Chandigarh Date : 09 December, 2025	Sushil Kapoor Director(Finance) & CFO DIN: 00063525 Place : Chandigarh Date : 09 December, 2025	Sanjaymohan Singh Rawat Company Secretary and Compliance Officer Membership No.: A74205 Place : Chandigarh Date : 09 December, 2025